$WGS Cashflow Statement | Understand Stock

$WGS

$62.74 +$1.48 (2.42%) Close

$WGS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Stock-based compensation expense
Change in fair value of financial liabilities
Deferred tax benefit
Provision for excess and obsolete inventory
Non-cash lease expense
Loss on extinguishment of debt
Third-party payor reserve release
Legal reserves
Change in third party payor reserves
Gain on sale of assets
Gain on debt forgiveness
Impairment loss
Amortization of debt issuance costs
Other
Change in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Due to/from related parties
Other assets
Accounts payable and accrued expenses
Contract liabilities
Other current liabilities
Other assets and liabilities

Net cash provided by (used in) operating activities
Investing activities
Acquisition of business, net of cash acquired and Consideration on escrow paid for Legacy GeneDx acquisition
Business Acquisitions
GeneDx
Total acquisition of business, net of cash acquired and Consideration on escrow paid for Legacy GeneDx acquisition
Purchases of marketable securities
Proceeds from sales of marketable securities
Proceeds from maturities of marketable securities
Purchases of property and equipment
Proceeds from sales of assets
Development of internal-use software assets
Net cash used in investing activities
Financing activities
Proceeds from issuance of Series C redeemable convertible preferred stock, net of issuance costs
Series B
Series C
Total proceeds from issuance of Series C redeemable convertible preferred stock, net of issuance costs
Proceeds from PIPE issuance
Proceeds from equity infusion from the merger, net of redemptions
Legacy Sema4 Shareholder payout
Payment of transaction costs
Stock Appreciation Rights payout
Proceeds from PIPE issuance, net of issuance costs
Proceeds from offerings, net of issuance costs
Proceeds from issuance of stock pursuant to employee stock purchase plan
Exercise of stock options
Capital contributions from ISMMS
Long-term debt principal payments
Finance lease payoff and principal payments
Proceeds from long-term debt
Debt issuance costs
Capital lease principal payments
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, at beginning of year
Cash, cash equivalents and restricted cash, at end of year
Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for taxes
Purchases of property and equipment in accounts payable and accrued expenses
Software development costs in accounts payable and accrued expenses
Non-cash Series A redeemable convertible preferred stock dividends declared and paid
Stock consideration paid pursuant to exercise of Perceptive warrant
Assets acquired under capital leases obligations
Debt issuance costs incurred but unpaid
Issuance of common stock for first OPKO Milestone Payment
Stock consideration paid for purchase of business
Lease liability from obtaining right-of-use asset

Comments